Icosapent Ethyl
Amarin Pharmaceutical
[]
 taking the stage at #aha2022 #latebreakingtrials in response to #respectepa we need more mechanistic and clinical data, ie. those with elevated hscrp or highest delta epa, to determine who will benefit from dual statin and epa therapy #wic 
Cardiology fellow @templecards | GW IM RES’21 | medical journalism @abc @abcnewshealth | editorial board #CardioSmart @ACCinTouch | @ASPCardio #AHAFIT #ACCFIT